MapLight Therapeutics, Inc. (MPLT) is a Healthcare stock trading at $11.53 (as of 2026-08-21), with a market capitalization of $523.89M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. MapLight Therapeutics, Inc. was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California. MapLight Therapeutics, Inc operates as a subsidiary of Catalyst4, Inc.
MapLight Therapeutics is a clinical-stage biopharmaceutical company developing drug candidates for patients with debilitating central nervous system disorders, and its revenue model is not described in the provided facts.
As a clinical-stage biopharmaceutical company, its path to profitability is structurally tied to successfully advancing specific clinical programs, which is reflected in the reported Phase 2 trial enrollment and randomized participant counts rather than commercial metrics.
Business quality (Weak): The company shows Phase 2 development progress via enrollment and randomization metrics, but the provided financials indicate no reported revenue and a very large negative operating margin, highlighting pre-commercial risk.
Valuation: At 3× earnings, MPLT trades 80% below the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.
| Price | $11.53 |
| Market Cap | $523.89M |
| Price / Book | 1.50 |
| Price / Sales | 59.25 |
| FCF Yield | -55.3% |
| Revenue (TTM) | $5.52M |
| Net Margin | -2920.5% |
| Revenue Growth (YoY) | 22.5% |
| EPS Growth (YoY) | -82.4% |
| FCF Growth (YoY) | 74.2% |
| Altman Z-Score | 12.45 (safe) |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Top Institutional Holder | NOVO HOLDINGS A/S ($74.95M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Christopher A. Kroeger |
| Employees | 109 |
| Country | US |
| IPO Date | 2025-10-24 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.